HC Wainwright Issues Pessimistic Estimate for MIRM Earnings

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) - Equities research analysts at HC Wainwright decreased their Q3 2025 EPS estimates for shares of Mirum Pharmaceuticals in a research note issued on Wednesday, November 13th. HC Wainwright analyst E. Arce now forecasts that the company will post earnings per share of $0.35 for the quarter, down from their prior forecast of $0.46. HC Wainwright currently has a "Buy" rating and a $66.00 price target on the stock. The consensus estimate for Mirum Pharmaceuticals' current full-year earnings is ($1.84) per share. HC Wainwright also issued estimates for Mirum Pharmaceuticals' Q4 2025 earnings at $0.61 EPS.

A number of other equities analysts have also issued reports on the stock. Leerink Partners increased their target price on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an "outperform" rating in a research report on Thursday, October 17th. Citigroup raised their target price on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a "buy" rating in a report on Wednesday. Cantor Fitzgerald raised their target price on shares of Mirum Pharmaceuticals from $50.00 to $60.00 and gave the stock an "overweight" rating in a report on Thursday, August 8th. Evercore ISI raised their target price on shares of Mirum Pharmaceuticals from $62.00 to $66.00 and gave the stock an "outperform" rating in a report on Thursday, August 8th. Finally, Robert W. Baird raised their target price on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the stock an "outperform" rating in a report on Wednesday. Ten investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $57.73.

Mirum Pharmaceuticals Price Performance

MIRM traded up $2.34 on Thursday, reaching $46.26. The company had a trading volume of 859,715 shares, compared to its average volume of 559,576. The company has a fifty day moving average of $39.96 and a 200-day moving average of $35.79. The company has a market capitalization of $2.21 billion, a P/E ratio of -23.55 and a beta of 1.16. The company has a current ratio of 3.28, a quick ratio of 3.09 and a debt-to-equity ratio of 1.34. Mirum Pharmaceuticals has a one year low of $23.14 and a one year high of $48.89.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.30) earnings per share for the quarter, topping analysts' consensus estimates of ($0.45) by $0.15. The business had revenue of $90.38 million for the quarter, compared to analysts' expectations of $81.99 million. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 40.98%. The company's revenue for the quarter was up 89.4% compared to the same quarter last year. During the same quarter last year, the company earned ($0.57) EPS.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MIRM. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Mirum Pharmaceuticals by 22.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company's stock worth $67,000 after acquiring an additional 318 shares during the last quarter. Amalgamated Bank grew its stake in shares of Mirum Pharmaceuticals by 60.8% in the second quarter. Amalgamated Bank now owns 1,357 shares of the company's stock worth $46,000 after acquiring an additional 513 shares during the last quarter. Arizona State Retirement System boosted its stake in Mirum Pharmaceuticals by 10.6% during the second quarter. Arizona State Retirement System now owns 9,210 shares of the company's stock worth $315,000 after buying an additional 883 shares in the last quarter. Quest Partners LLC boosted its stake in Mirum Pharmaceuticals by 7,513.3% during the second quarter. Quest Partners LLC now owns 1,142 shares of the company's stock worth $39,000 after buying an additional 1,127 shares in the last quarter. Finally, Russell Investments Group Ltd. boosted its stake in Mirum Pharmaceuticals by 11.7% during the first quarter. Russell Investments Group Ltd. now owns 17,481 shares of the company's stock worth $439,000 after buying an additional 1,825 shares in the last quarter.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.